Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Levy G et al. | Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. | 2004 | Transplantation | pmid:15201658 |
Ajiki T et al. | Generation of donor hematolymphoid cells after rat-limb composite grafting. | 2003 | Transplantation | pmid:12640301 |
Tsuchiya N et al. | Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. | 2004 | Transplantation | pmid:15502717 |
Stegall MD et al. | Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus. | 1997 | Transplantation | pmid:9422416 |
David-Neto E et al. | The dynamics of glucose metabolism under calcineurin inhibitors in the first year after renal transplantation in nonobese patients. | 2007 | Transplantation | pmid:17627237 |
Demetris AJ et al. | Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients. | 1992 | Transplantation | pmid:1374944 |
Al-Uzri A et al. | Posttransplant diabetes mellitus in pediatric renal transplant recipients: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). | 2001 | Transplantation | pmid:11579294 |
Nogueira JM et al. | A comparison of recipient renal outcomes with laparoscopic versus open live donor nephrectomy. | 1999 | Transplantation | pmid:10096529 |
Egawa H et al. | Isolated alkaline phosphatemia following pediatric liver transplantation in the FK506 ERA. | 1995 | Transplantation | pmid:7533958 |
Ekberg H et al. | The challenge of achieving target drug concentrations in clinical trials: experience from the Symphony study. | 2009 | Transplantation | pmid:19424036 |
Guerville F et al. | Transplantation with pathologic kidneys to improve the pool of donors: an example of shunt nephritis. | 2012 | Transplantation | pmid:22487813 |
Chapman WC et al. | Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in De Novo Liver Transplant Recipients: 24-Month Results for the North American Subpopulation. | 2017 | Transplantation | pmid:28121741 |
Becker T et al. | Patient outcomes in two steroid-free regimens using tacrolimus monotherapy after daclizumab induction and tacrolimus with mycophenolate mofetil in liver transplantation. | 2008 | Transplantation | pmid:19104406 |
Oike F et al. | A 12-day course of FK506 allows long-term acceptance of semi-identical liver allograft in inbred miniature swine. | 2000 | Transplantation | pmid:10868630 |
Gloor JM et al. | Subclinical rejection in tacrolimus-treated renal transplant recipients. | 2002 | Transplantation | pmid:12131699 |
Borni-Duval C et al. | Risk factors for BK virus infection in the era of therapeutic drug monitoring. | 2013 | Transplantation | pmid:23778568 |
Jain A et al. | Long-term outcome of adding mycophenolate mofetil to tacrolimus for nephrotoxicity following liver transplantation. | 2005 | Transplantation | pmid:16210976 |
Mourer JS et al. | Late calcineurin inhibitor withdrawal prevents progressive left ventricular diastolic dysfunction in renal transplant recipients. | 2012 | Transplantation | pmid:22955227 |
Florman S et al. | Once-daily tacrolimus extended release formulation: experience at 2 years postconversion from a Prograf-based regimen in stable liver transplant recipients. | 2007 | Transplantation | pmid:17589349 |
Yoo MC et al. | Steroid-free Liver Transplantation Using Rabbit Antithymocyte Globulin Induction in 500 Consecutive Patients. | 2015 | Transplantation | pmid:25539464 |